糖尿病肾病是2型糖尿病患者常见微血管并发症之一,也是我国终末期肾病患者的常见病因。近年来多项随机对照试验发现,二肽基肽酶4抑制剂、钠-葡萄糖共转动蛋白2抑制剂、胰高血糖素样肽1受体激动剂等新型降糖药物除降糖作用之外,部分还具有肾脏保护作用,其中钠-葡萄糖共转动蛋白2抑制剂、胰高血糖素样肽1受体激动剂已被相关临床指南或专家共识推荐用于2型糖尿病患者合并慢性肾脏病患者,为临床预防和治疗糖尿病肾病、延缓糖尿病肾病进展提供了新选择。本文结合最新指南及临床试验总结、分析了新型降糖药物对2型糖尿病患者的肾脏获益,以期为临床更好地应用新型降糖药物提供参考。Diabetic nephropathy,a common microvascular complication of type 2 diabetes,has become one of the common causes of end-stage renal disease in China.Several randomized controlled studies conducted in recent years found that,some novel anti-diabetic agents including dipeptidyl peptidase-4 inhibitor,sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist,have significant renal protection outcomes beside hypoglycemia effect in patients with type 2 diabetes,moreover sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist were recommended by clinical guideline or consensus in the prevention and delay of diabetic kidney disease.This paper summarized and analyzed the outcome of novel anti-diabetic agents in renal protection outcomes in patients with type 2 diabetes based on recent clinical guidelines and related randomized controlled trials,in order to provide a reference for the better application of novel antidiabetic agents in practice.
机构地区首都医科大学附属北京同仁医院内分泌科
出处《中国全科医学》 CAS 北大核心 2021年第18期2245-2250,共6页Chinese General Practice
关键词糖尿病 2型 降血糖药 二肽基肽酶Ⅳ抑制剂 钠-葡萄糖共转运蛋白2抑制剂 胰高血糖素样肽1 新型降糖药物 肾脏获益 述评Diabetes mellitus,type 2 Hypoglycemic agents Dipeptidyl-peptidaseⅣinhibitors Sodium-glucose transporter 2 inhibitors Glucagon-like peptide 1 Newer classes of antidiabetic agents Kidney benefits Editorial
分类号R587.1 [医药卫生—内分泌]
